Revance Therapeutics, Inc.

DB:RTI Stock Report

Market Cap: €375.7m

Revance Therapeutics Management

Management criteria checks 2/4

Revance Therapeutics' CEO is Mark Foley, appointed in Oct 2019, has a tenure of 5.08 years. total yearly compensation is $10.07M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth €3.96M. The average tenure of the management team and the board of directors is 5.3 years and 5.4 years respectively.

Key information

Mark Foley

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage7.2%
CEO tenure5.1yrs
CEO ownership1.1%
Management average tenure5.3yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Foley's remuneration changed compared to Revance Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$303m

Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$292m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Sep 30 2018n/an/a

-US$138m

Jun 30 2018n/an/a

-US$136m

Mar 31 2018n/an/a

-US$128m

Dec 31 2017US$338kn/a

-US$121m

Compensation vs Market: Mark's total compensation ($USD10.07M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Foley (59 yo)

5.1yrs

Tenure

US$10,068,915

Compensation

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director5.1yrsUS$10.07m1.06%
€ 4.0m
Tobin Schilke
CFO & Principal Accounting Officer6yrsUS$3.97m0.092%
€ 347.4k
Dwight Moxie
Chief Legal Officer & General Counsel4.8yrsUS$3.53m0.046%
€ 171.3k
Jessica Serra
Head of Investor Relations & ESGno datano datano data
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications7.9yrsno datano data
Taryn Conway
Vice President of Marketing5.6yrsno datano data
Amie Krause
Chief People Officer1.7yrsno datano data
Conor Gallagher
Head of Medical Affairs & Aesthetics6.5yrsno datano data
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead1.8yrsno data0.10%
€ 375.9k
Erica Jordan
Chief Commercial Officerno datano data0.11%
€ 411.4k

5.3yrs

Average Tenure

49yo

Average Age

Experienced Management: RTI's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director7.2yrsUS$10.07m1.06%
€ 4.0m
Angus Russell
Independent Chairman10.7yrsUS$346.03k0.049%
€ 184.5k
Jill Beraud
Independent Director5.4yrsUS$317.53k0.042%
€ 156.2k
Julian Gangolli
Independent Director8.3yrsUS$305.03k0.043%
€ 161.6k
Vladimir Coric
Independent Director1.7yrsUS$421.49k0.020%
€ 74.4k
Olivia Ware
Independent Director3.7yrsUS$295.03k0.030%
€ 113.4k
Carey Kolaja
Independent Director3.7yrsUS$304.18k0.030%
€ 113.1k
Christian Nolet
Independent Director5.3yrsUS$315.03k0.042%
€ 156.2k

5.4yrs

Average Tenure

65yo

Average Age

Experienced Board: RTI's board of directors are considered experienced (5.4 years average tenure).